Good clinical endpoints with denosumab in XXXX and cancer.

@entity1 @entity263 @entity174 @entity2931 @entity604 @entity170 @entity342
BACKGROUND: @entity604 associated with low @entity2931 levels in postmenopausal @entity1 , and with @entity342 deprivation therapy in @entity1 with @entity263 , result in an increased incidence of @entity174 . Denosumab has been shown to increase bone mineral density in these two conditions. OBJECTIVES/METHODS: The objective of this evaluation is to review the clinical trials that have studied clinical endpoints in these conditions. RESULTS: FREEDOM (Fracture Reduction Evaluation of Denosumab in @entity170 Every 6 Months) was an International Phase III clinical trial that measured the clinical endpoints with denosumab in postmenopausal @entity1 with @entity170 . At 36 months, new @entity174 had occurred in 7.2% of subjects in the placebo group and this was lowered to 2.3% of subjects treated with denosumab. HALT (Denosumab Hormone Ablation Bone Loss Trial) studied the clinical endpoints in @entity1 with non-metastatic @entity263 receiving @entity342 -deprivation therapy. The incidence of @entity174 was significantly lower in the denosumab group (1.5%) than in the placebo group (3.9%). The incidence of adverse effects with denosumab in both clinical trials was low. CONCLUSIONS: Denosumab reduces the incidence of @entity174 in postmenopausal @entity1 with @entity170 and in @entity1 with non-metastatic @entity263 receiving @entity342 -deprivation therapy. Denosumab is well tolerated.
